Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

Obinutuzumab B-cell depleting therapy is more effective than standard care in treating patients with active proliferative lupus nephritis.

Cabaletta’s new data slice for its investigational CD19-CAR T cell therapy shows “robust benefit” for patients with lupus and ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Members of the Artiva management team will also be available to participate in in-person investor meetings with investors who are registered to attend the conference.

Cabaletta Bio (NASDAQ:CABA – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a note issued to ...

Adicet Bio, Inc. (NASDAQ:ACET), currently trading at $0.99 with a market capitalization of $81.7 million, is a clinical-stage biopharmaceutical company focused on developing novel cell therapies based ...

StockNews.com downgraded shares of Aurinia Pharmaceuticals (NASDAQ:AUPH – Free Report) (TSE:AUP) from a strong-buy rating to a buy rating in a report issued on Wednesday. Aurinia Pharmaceuticals Price ...

Vertex Pharmaceuticals Incorporated today announced management participation in three upcoming investor conferences. Stuart Arbuckle, Executive Vice President and Chief Operating Officer, and David ...

The Protein Sequencing Companytm, and several distinguished researchers will be presenting new research and applications at the 2025 Advances in Genome Biology and Technology ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...